Profound Medical (TSE:PRN) Third Quarter 2024 Results
Key Financial Results
- Net loss: US$9.36m (loss widened by 68% from 3Q 2023).
- US$0.38 loss per share (further deteriorated from US$0.26 loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Profound Medical Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 5.2%. Earnings per share (EPS) also missed analyst estimates by 27%.
Looking ahead, revenue is forecast to grow 48% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in North America.
Performance of the market in Canada.
The company's shares are up 16% from a week ago.
Risk Analysis
We don't want to rain on the parade too much, but we did also find 1 warning sign for Profound Medical that you need to be mindful of.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSX:PRN
Profound Medical
Operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland.
Flawless balance sheet with high growth potential.
